Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR) has revealed that its ZokinvyTM (lonafarnib) has got permission from the FDA for the treatment of Hutchinson-Gilford Progeria Syndrome (HGPS or Progeria) and processing-deficient Progeroid Laminopathies (PL). These syndromes double the death rate in young patients. Eiger BioPharmaceuticals revealed